SEARCH

SEARCH BY CITATION

Acknowledgement

  1. Acknowledgement
  2. References

The authors have no proprietary or commercial interest in any materials discussed in the article

References

  1. Acknowledgement
  2. References
  • Chan WM, Lai TY, Lai RY, Tang EW, Liu DT & Lam DS (2008): Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28: 8593.
  • Maier M, Valet V, Feucht N, Fiore B, Mohrenfels CWV & Lohmann C (2008): Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for central serous chorioretinopathy: a case series. Acta Ophthalmol 86. Special Issue: Abstracts from the 2008 European Association for Vision and Eye Research Conference.
  • Orobia AM, Alperte JI, Alaman AS, Gabas JM, Lafuente N & Cristobal J (2008): Photodynamic therapy without verteporfin for central serous chorioretinopathy. Acta Ophthalmol 86. Special Issue: Abstracts from the 2008 European Association for Vision and Eye Research Conference.
  • Torres-Soriano M, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober M & Quiroz-Mercado H (2008): A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports). Graefes Arch Clin Exp Ophthalmol 249: 12351239.